Skip to content

    OSEL Devices

    OSELDEVICE
    Healthcare·27 May 2025
    Management Summary

    OSEL Devices reported a strong FY25 with an 18% consolidated EBITDA margin and an estimated H2 revenue of ₹99 crores. The company announced a significant strategic move by securing an exclusive license for Philips mobile phones and tablets in India, projecting 15-20% EBITDA margins from this new segment. OSEL is targeting a 25% CAGR for its existing healthcare LED and LED display businesses, alongside plans for international expansion and entry into the retail segment for hearing aids, despite an increase in receivable days.

    Highlights

    5
    • Strong growth outlook with 25% CAGR projected for existing divisions.

    • Strategic entry into mobile devices with exclusive Philips brand license in India.

    • Diversified revenue streams with new OEM business contributing 20% by FY26.

    • Targeting higher profitability by entering the retail segment for hearing aids.

    • International expansion plans supported by a new manufacturing setup in JNPT.

    Concerns

    3
    • Increase in receivable days from 20% of sales in FY24 to 35% in FY25, expected to remain 30-35% next year.

    • Initial outsourcing of Philips mobile phone manufacturing, with in-house setup planned only after business stabilization.

    • Analyst concern regarding the six-month gap in SEBI reporting, leading to market uncertainty.

    What Changed1

    vs Q2 FY26

    Risks discussed5 → 4 (-1)
    Key financials

    Metrics

    3

    Periods

    3

    Headline

    1
    • H2 FY25 Revenue
      ₹99 Cr

    Q4 FY25

    1
    • Revenue
      ₹47.5 Cr

    FY25

    1
    • EBITDA Margin
      18%

    Segment breakdown

    Healthcare LED Devices (Current Mix)
    55% Revenue Contribution
    LED Display Business (Current Mix)
    45% Revenue Contribution
    Hearing Aid Units Sold (FY25)
    1.45 lakhs Volume
    List

    Order Book

    medium confidence

    Total Value

    ₹ 42.5 crores

    as of 2025-05-27

    range

    Pipeline

    other

    Very healthy numbers in pipeline for tenders and projects, but not quantified.

    "Management indicated a healthy pipeline of tenders and projects, but did not quantify the value."

    Source:
    Q&A

    Capital allocation

    3
    medium confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Debt

    Debt disclosed

    Liquidity

    Liquidity disclosed

    The company has given short-term loans and advances of ₹38.98 crores, including payments for JNPT land and a Bangalore office where registry is pending.

    Guidance & targets

    10
    CategoryTargetPriority
    Growth
    CAGR for both divisions
    25%
    High
    Receivables
    Receivable days as % of sales
    30-35%
    Medium
    Revenue Mix
    Philips phones contribution
    30%
    High
    Revenue Mix
    Display business contribution
    30%
    High
    Revenue Mix
    Medical equipment (hearing aids) contribution
    20%
    High
    Revenue Mix
    OEM business contribution
    20%
    High
    Profitability
    EBITDA margins for Philips mobile phones
    15-20%
    High
    Profitability
    PAT margins/percentages
    maintain current
    High
    Market Penetration
    Philips mobile phones market penetration
    small 5%
    Low
    Product Launch
    Smartphones launch
    by this year end
    Medium

    Receivable Days Stabilization

    next year
    Current35% of sales (FY25)
    TargetStabilization around 30-35% of sales

    Why it matters

    Indicates improvement in working capital management and cash flow efficiency.

    I think it will remain to around 30%-35% for next year, actually.

    How to verify

    key_financials.metrics[label='Receivable Days']

    Risks & concerns

    4
    RiskSeverity

    Six-month reporting gap for SEBI filings

    Analyst noted SEBI's six-month reporting gap creates uncertainty for investors; management agreed to consider quarterly numbers.Analyst acknowledged

    medium

    Increased receivable days

    Receivable days increased from 20% in FY24 to 35% in FY25, attributed to LED business working cycle and advance payments, expected to stabilize at 30-35% next year.Analyst acknowledged

    medium

    Initial outsourcing of Philips manufacturing

    Philips mobile phone manufacturing is initially outsourced for trials and stability, with plans to bring it in-house later, implying potentially lower initial margins/control.Management acknowledged

    low

    Costly direct smartphone launch

    Management views a direct launch of smartphones as a 'costly affair' and prefers a phased approach starting with feature phones to avoid inducing money now.Management acknowledged

    low

    Q&A highlights

    8

    “So, with the Philips deal, basically, we have got the brand license for Philips to a specific category which is mobile phone, tablets, and other IT products. Under this, we will be manufacturing, selling, distribution, marketing. Everything comes under our scope. And we are fully responsible for the complete operations of this particular category of Philips brand within India.”

    Clarifies OSEL's comprehensive role in the Philips mobile business in India, including manufacturing and sales, and how royalties are handled.

    asked by Agastya Dave

    2 min read5 chapters

    Detailed Narrative

    01

    Strategic Entry into Mobile Devices with Philips

    OSEL Devices has secured an exclusive license to launch Philips mobile phones and tablets in the Indian market. This partnership grants OSEL the rights to design, manufacture, market, and distribute these products, aiming for 15-20% EBITDA margins from this new segment. The company plans a phased entry, starting with feature phones within the current month to gain market penetration, with smartphones expected to be launched by year-end, avoiding the high costs of a direct smartphone launch.

    02

    Diversified Revenue Streams and Growth Outlook

    Currently, OSEL's revenue is split with 55% from healthcare LED devices and 45% from LED display business. For FY26, the company projects a diversified revenue mix: 30% from Philips phones, 30% from display, 20% from medical equipment (hearing aids), and 20% from a new OEM business. OSEL is targeting a 25% CAGR for its existing divisions, driven by innovation, operational excellence, and market expansion, with growth in hearing aids coming from both volume and pricing increases as they target the retail segment.

    03

    International Expansion and Manufacturing Capacity

    To support its international ambitions, OSEL is establishing a manufacturing facility in the JNPT free zone, having already paid ₹8-10 crores for the land. This facility will cater to international customers, particularly for large format displays, leveraging the 'Make in India' initiative as multinational companies shift away from China imports. While Philips mobile phone manufacturing is initially outsourced, OSEL intends to bring it in-house once the business achieves stability.

    04

    Working Capital Management and Receivables

    The company observed an increase in receivable days, rising from 20% of sales in FY24 to 35% in FY25. This was primarily attributed to the working cycle of the LED business and strategic advance payments for cheaper prices. Management anticipates that receivable days will stabilize around 30-35% next year, influenced by the integration of the Philips business.

    05

    Financial Performance and Profitability Targets

    OSEL Devices reported a consolidated EBITDA margin of 18% for the last fiscal year. For the new Philips mobile phone segment, the company is targeting EBITDA margins of 15-20%. Management expressed its intention to maintain current PAT margins or percentages going forward, indicating a focus on sustaining profitability amidst its expansion and diversification efforts.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.